Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010

Jacques Baillargeon, Randall Urban, Yong Fang Kuo, Holly M. Holmes, Mukaila Raji, Abraham Morgentaler, Bret Howrey, Yu Li Lin, Kenneth Ottenbacher

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objectives. The Endocrine Society recommends testosterone therapy only in men with low serum testosterone levels, consistent symptoms of hypogonadism, and no signs of prostate cancer. We assessed screening and monitoring patterns in men receiving testosterone therapy in the U.S.Methods. We conducted a retrospective cohort study of 61,474 men aged $40 years, and with data available in one of the nation’s largest commercial insurance databases, who received at least one prescription for testosterone therapy from 2001 to 2010.Results. In the 12 months before initiating treatment, 73.4% of male tes- tosterone users received a serum testosterone test and 60.7% received a prostate-specific antigen (PSA) test. Among men who were tested, 19.5% did not meet Endocrine Society guidelines for low testosterone. In the 12 months after initiating treatment, 52.4% received a serum testosterone test and 43.3% received a PSA test. Multivariable analyses showed that those seen by either an endocrinologist or urologist were more likely to receive appropriate tests. Conclusions. A substantial number of men prescribed testosterone therapy did not receive testosterone or PSA testing before or after initiating treatment. In addition, almost one out of five treated men had baseline serum testosterone values above the threshold defined as normal by the Endocrine Society. Men treated by endocrinologists and urologists were more likely to have been treated according to guideline recommendations than men treated by other specialties, including primary care.

Original languageEnglish (US)
Pages (from-to)143-152
Number of pages10
JournalPublic Health Reports
Volume130
Issue number2
StatePublished - 2015

Fingerprint

Testosterone
Prostate-Specific Antigen
Therapeutics
Serum
Guidelines
Hypogonadism
Insurance
Prescriptions
Prostatic Neoplasms
Primary Health Care
Cohort Studies
Retrospective Studies
Databases

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010. / Baillargeon, Jacques; Urban, Randall; Kuo, Yong Fang; Holmes, Holly M.; Raji, Mukaila; Morgentaler, Abraham; Howrey, Bret; Lin, Yu Li; Ottenbacher, Kenneth.

In: Public Health Reports, Vol. 130, No. 2, 2015, p. 143-152.

Research output: Contribution to journalArticle

@article{378b80f38aa742b29594eade1c1f90fa,
title = "Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010",
abstract = "Objectives. The Endocrine Society recommends testosterone therapy only in men with low serum testosterone levels, consistent symptoms of hypogonadism, and no signs of prostate cancer. We assessed screening and monitoring patterns in men receiving testosterone therapy in the U.S.Methods. We conducted a retrospective cohort study of 61,474 men aged $40 years, and with data available in one of the nation’s largest commercial insurance databases, who received at least one prescription for testosterone therapy from 2001 to 2010.Results. In the 12 months before initiating treatment, 73.4{\%} of male tes- tosterone users received a serum testosterone test and 60.7{\%} received a prostate-specific antigen (PSA) test. Among men who were tested, 19.5{\%} did not meet Endocrine Society guidelines for low testosterone. In the 12 months after initiating treatment, 52.4{\%} received a serum testosterone test and 43.3{\%} received a PSA test. Multivariable analyses showed that those seen by either an endocrinologist or urologist were more likely to receive appropriate tests. Conclusions. A substantial number of men prescribed testosterone therapy did not receive testosterone or PSA testing before or after initiating treatment. In addition, almost one out of five treated men had baseline serum testosterone values above the threshold defined as normal by the Endocrine Society. Men treated by endocrinologists and urologists were more likely to have been treated according to guideline recommendations than men treated by other specialties, including primary care.",
author = "Jacques Baillargeon and Randall Urban and Kuo, {Yong Fang} and Holmes, {Holly M.} and Mukaila Raji and Abraham Morgentaler and Bret Howrey and Lin, {Yu Li} and Kenneth Ottenbacher",
year = "2015",
language = "English (US)",
volume = "130",
pages = "143--152",
journal = "Public Health Reports",
issn = "0033-3539",
publisher = "Association of Schools of Public Health",
number = "2",

}

TY - JOUR

T1 - Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010

AU - Baillargeon, Jacques

AU - Urban, Randall

AU - Kuo, Yong Fang

AU - Holmes, Holly M.

AU - Raji, Mukaila

AU - Morgentaler, Abraham

AU - Howrey, Bret

AU - Lin, Yu Li

AU - Ottenbacher, Kenneth

PY - 2015

Y1 - 2015

N2 - Objectives. The Endocrine Society recommends testosterone therapy only in men with low serum testosterone levels, consistent symptoms of hypogonadism, and no signs of prostate cancer. We assessed screening and monitoring patterns in men receiving testosterone therapy in the U.S.Methods. We conducted a retrospective cohort study of 61,474 men aged $40 years, and with data available in one of the nation’s largest commercial insurance databases, who received at least one prescription for testosterone therapy from 2001 to 2010.Results. In the 12 months before initiating treatment, 73.4% of male tes- tosterone users received a serum testosterone test and 60.7% received a prostate-specific antigen (PSA) test. Among men who were tested, 19.5% did not meet Endocrine Society guidelines for low testosterone. In the 12 months after initiating treatment, 52.4% received a serum testosterone test and 43.3% received a PSA test. Multivariable analyses showed that those seen by either an endocrinologist or urologist were more likely to receive appropriate tests. Conclusions. A substantial number of men prescribed testosterone therapy did not receive testosterone or PSA testing before or after initiating treatment. In addition, almost one out of five treated men had baseline serum testosterone values above the threshold defined as normal by the Endocrine Society. Men treated by endocrinologists and urologists were more likely to have been treated according to guideline recommendations than men treated by other specialties, including primary care.

AB - Objectives. The Endocrine Society recommends testosterone therapy only in men with low serum testosterone levels, consistent symptoms of hypogonadism, and no signs of prostate cancer. We assessed screening and monitoring patterns in men receiving testosterone therapy in the U.S.Methods. We conducted a retrospective cohort study of 61,474 men aged $40 years, and with data available in one of the nation’s largest commercial insurance databases, who received at least one prescription for testosterone therapy from 2001 to 2010.Results. In the 12 months before initiating treatment, 73.4% of male tes- tosterone users received a serum testosterone test and 60.7% received a prostate-specific antigen (PSA) test. Among men who were tested, 19.5% did not meet Endocrine Society guidelines for low testosterone. In the 12 months after initiating treatment, 52.4% received a serum testosterone test and 43.3% received a PSA test. Multivariable analyses showed that those seen by either an endocrinologist or urologist were more likely to receive appropriate tests. Conclusions. A substantial number of men prescribed testosterone therapy did not receive testosterone or PSA testing before or after initiating treatment. In addition, almost one out of five treated men had baseline serum testosterone values above the threshold defined as normal by the Endocrine Society. Men treated by endocrinologists and urologists were more likely to have been treated according to guideline recommendations than men treated by other specialties, including primary care.

UR - http://www.scopus.com/inward/record.url?scp=84923674106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923674106&partnerID=8YFLogxK

M3 - Article

VL - 130

SP - 143

EP - 152

JO - Public Health Reports

JF - Public Health Reports

SN - 0033-3539

IS - 2

ER -